Table 1 Patient characteristics
From: Voriconazole and posaconazole therapeutic drug monitoring: a retrospective study
Characteristics | Overall (n = 151) | Voriconazole (n = 122) | Posaconazole (n = 38) |
|---|---|---|---|
Male | 79 (48) | 60 (49) | 22 (58) |
Age (year) (median [IQR]) | 50 (33–60) | 50 (33–60) | 48 (33–60) |
Weighta (kg) (median [IQR]) | 70.8 (59.8–82.6) | 69.7 (58.6–82.1) | 74.0 (63.4–84.0)b |
Race and ethnicity | |||
 Caucasian | 93 (62) | 77 (63) | 21 (55) |
 African American | 10 (7) | 7 (6) | 3 (8) |
 American India or Alaskan native | 3 (2) | 3 (2) | 1 (3) |
 Asian | 3 (2) | 3 (2) | 0 |
 Hispanic | 19 (12) | 12 (10) | 8 (21) |
 Unknown | 23 (15) | 20 (17) | 5 (13) |
Critically ill | 68 (45) | 57 (47) | 16 (42) |
Transplant status | |||
 Solid organ recipients | 23 (15) | 18 (15) | 7 (18) |
 Bone marrow recipients | 38 (25) | 33 (27) | 10 (26) |
Comorbidities | |||
 Cystic fibrosis | 18 (12) | 17 (14) | 1 (3) |
Type of infection | |||
 Prophylaxis | 9 (6) | 5 (4) | 4 (11) |
 Possible | 32 (21) | 27 (22) | 10 (26) |
 Probable | 57 (38) | 51 (42) | 6 (16) |
 Proven | 53 (35) | 39 (32) | 18 (47) |
Identified organism (n = 103) |  | (n = 82) | (n = 21) |
 Candida spp. |  | 31 (38) | 3 (14) |
 Aspergillus spp. |  | 34 (41) | 3 (14) |
 Mucor |  | 0 | 11 (52) |
 Scedosporium spp. |  | 7 (9) | 0 |
 Cryptococcus |  | 1 (1) | 1 (4) |
 Other |  | 9 (11) | 3 (14) |
Outcomes | |||
 Achieved a mean therapeutic level |  | 74 (61) | 22 (58) |
 Survived to hospital discharge | 109 (72) | 90 (74) | 26 (68) |
 Treatment failure | 39 (26) | 33 (27) | 7 (18) |